Preclinical and clinical aspects of the dipeptidyl peptidase-4 inhibitor anagliptin

Folia Pharmacologica Japonica

Volumn 141, Issue 6, 2013, Pages 339-349

  Tsubamoto, Yoshiharu ^a   Goto, Moritaka ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84926222215     PISSN: 00155691     EISSN: 13478397     Source Type: Journal    
DOI: 10.1254/fpj.141.339     Document Type: Review

References (23)

1. IDF Diabetes Atlas 5th edition. International Diabetes Federation. 2012.
2. Japanese Text
3. Nauck MA, et al. J Clin Endocrinol Metab. 1986;63:492-498.
4. Drucker DJ, et al. Lancet. 2006;368:1696-1705.
5. Vilsboll T, et al. J Clin Endocrinol Metab. 2003;88:220-224.
6. Mentlein R, et al. Eur J Biochem. 1993;214:829-835.
7. Mentlein R, et al. Regul Pept. 1999;85:9-24.
8. Lambeir AM, et al. Crit Rev Clin Lab Sci. 2003;40:209-294.
9. Holst JJ. Physiol Rev. 2007;87:1409-1439.
10. Wang Q, et al. Diabetologia. 2002;45:1263-1273.
11. Drucker DJ. Diabetes Care. 2003;26:2929-2940.
12. Deacon CF, et al. Expert Opin Investig Drugs. 2004;13:1091-1102.
13. Kieffer TJ, et al. Endocrinology. 1995;136:3585-3596.
14. Lankas GR, et al. Diabetes. 2005;54:2988-2994.
15. Goto M, et al. Diabetes. 2007;Suppl 1A382.
16. Japanese Text
17. Japanese Text
18. Qualmann C, et al. Scand J Gastroenterol. 1995;30:892-896.
19. Yasuda N, et al. Biochem Biophys Res Commun. 2002;298:779-784.
20. Japanese Text
21. Japanese Text
22. Japanese Text
23. Japanese Text